Successful placement with professional investors with a very diversified base of international and French investors for an amount of €2.5 million.
Sustained participation of individuals via the PrimaryBid platform with an offer oversubscribed 2.3 times and for an amount of €1.4 million, allocated to €0.6 million.
Resources adapted to anticipate the implementation of the Phase 3 clinical study of NFL-101 and set up a licensing partnership under the best conditions, and to advance the development of NFL-301. Secure cash flow horizon until the end of the 2nd quarter of 2025.
Payment for delivery of new shares on April 16, 2024.
NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical medicines for the treatment of dependencies and addictions, today announces the strong success of its fundraising for an amount of 3,089,175.75 euros per channel capital increases with elimination of shareholders’ preferential subscription rights for the benefit of professional investors up to €2.5 million on the one hand, and individual investors via the PrimaryBid platform up to €0 on the other hand, €6 million (the “Transaction”).